Spark's price for Luxturna blindness gene therapy too high: ICER

(Reuters) - The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

Spark's price for Luxturna blindness gene therapy too high: ICER
Read More


Bagikan Berita Ini